DXCM vs. RMD

Last updated Apr 1, 2026

Compare and contrast key facts about DexCom, Inc. (DXCM) and ResMed Inc. (RMD).

Performance

DXCM vs. RMD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in DexCom, Inc. (DXCM) and ResMed Inc. (RMD). The values are adjusted to include any dividend payments, if applicable.

DXCM vs. RMD - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
DXCM DexCom, Inc.	-5.38%	-14.66%	-37.33%	9.58%	-15.64%	45.23%	69.02%	82.59%	108.75%	-3.87%
RMD ResMed Inc.	-6.59%	6.26%	34.18%	-16.55%	-19.47%	23.41%	38.33%	37.85%	36.38%	39.06%

Fundamentals

EPS DXCM : $2.07 RMD : $15.16
PE Ratio DXCM : 30.40 RMD : 14.81
PEG Ratio DXCM : 0.72 RMD : 0.46
PS Ratio DXCM : 5.45 RMD : 4.08
Total Revenue (TTM) DXCM : $4.66B RMD : $5.40B
Gross Profit (TTM) DXCM : $2.80B RMD : $3.29B
EBITDA (TTM) DXCM : $1.34B RMD : $1.96B

Returns By Period

In the year-to-date period, DXCM achieves a -5.38% return, which is significantly higher than RMD's -6.59% return. Over the past 10 years, DXCM has underperformed RMD with an annualized return of 14.02%, while RMD has yielded a comparatively higher 15.62% annualized return.

DXCM

• 1D: 1.45%
• 1M: -14.48%
• YTD: -5.38%
• 6M: -6.67%
• 1Y: -8.04%
• 3Y*: -18.54%
• 5Y*: -7.23%
• 10Y*: 14.02%

RMD

• 1D: 2.02%
• 1M: -12.40%
• YTD: -6.59%
• 6M: -17.61%
• 1Y: 1.18%
• 3Y*: 1.78%
• 5Y*: 3.81%
• 10Y*: 15.62%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

DXCM vs. RMD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DXCM

DXCM Risk / Return Rank: 34
DXCM Sharpe Ratio Rank: 34
DXCM Sortino Ratio Rank: 31
DXCM Omega Ratio Rank: 32
DXCM Calmar Ratio Rank: 37
DXCM Martin Ratio Rank: 37

RMD

RMD Risk / Return Rank: 41
RMD Sharpe Ratio Rank: 44
RMD Sortino Ratio Rank: 37
RMD Omega Ratio Rank: 36
RMD Calmar Ratio Rank: 45
RMD Martin Ratio Rank: 46

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DXCM vs. RMD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for DexCom, Inc. (DXCM) and ResMed Inc. (RMD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DXCM	RMD	Difference
Sharpe ratio Return per unit of total volatility	-0.18	0.05	-0.23
Sortino ratio Return per unit of downside risk	0.04	0.26	-0.22
Omega ratio Gain probability vs. loss probability	1.01	1.03	-0.03
Calmar ratio Return relative to maximum drawdown	-0.19	0.12	-0.31
Martin ratio Return relative to average drawdown	-0.38	0.28	-0.66
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DXCM vs. RMD - Sharpe Ratio Comparison

The current DXCM Sharpe Ratio is -0.18, which is lower than the RMD Sharpe Ratio of 0.05. The chart below compares the historical Sharpe Ratios of DXCM and RMD, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	DXCM	RMD	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.18	0.05	-0.23
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.16	0.12	-0.28
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.29	0.50	-0.21
Sharpe Ratio (All Time) Calculated using the full available price history	0.29	0.53	-0.25

Correlation

The correlation between DXCM and RMD is 0.33, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

DXCM vs. RMD - Dividend Comparison

DXCM has not paid dividends to shareholders, while RMD's dividend yield for the trailing twelve months is around 1.04%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
DXCM DexCom, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
RMD ResMed Inc.	1.04%	0.94%	0.88%	1.07%	0.83%	0.62%	0.73%	0.98%	1.26%	1.61%	2.03%	2.16%

Drawdowns

DXCM vs. RMD - Drawdown Comparison

The maximum DXCM drawdown since its inception was -94.61%, which is greater than RMD's maximum drawdown of -61.61%. Use the drawdown chart below to compare losses from any high point for DXCM and RMD.

Drawdown Indicators

	DXCM	RMD	Difference
Max Drawdown Largest peak-to-trough decline	-94.61%	-61.61%	-33.00%
Max Drawdown (1Y) Largest decline over 1 year	-38.75%	-24.74%	-14.01%
Max Drawdown (5Y) Largest decline over 5 years	-66.32%	-53.99%	-12.33%
Max Drawdown (10Y) Largest decline over 10 years	-66.32%	-53.99%	-12.33%
Current Drawdown Current decline from peak	-61.43%	-23.22%	-38.21%
Average Drawdown Average peak-to-trough decline	-35.79%	-15.91%	-19.88%
Ulcer Index Depth and duration of drawdowns from previous peaks	19.27%	10.55%	+8.72%

Volatility

DXCM vs. RMD - Volatility Comparison

DexCom, Inc. (DXCM) has a higher volatility of 9.22% compared to ResMed Inc. (RMD) at 6.17%. This indicates that DXCM's price experiences larger fluctuations and is considered to be riskier than RMD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DXCM	RMD	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.22%	6.17%	+3.05%
Volatility (6M) Calculated over the trailing 6-month period	27.63%	17.04%	+10.59%
Volatility (1Y) Calculated over the trailing 1-year period	43.67%	25.62%	+18.05%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	46.76%	31.07%	+15.69%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	48.31%	31.41%	+16.90%

Financials

DXCM vs. RMD - Profitability Comparison

The chart below illustrates the profitability comparison between DexCom, Inc. and ResMed Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

DXCM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, DexCom, Inc. reported a gross profit of 792.70M and revenue of 1.26B. Therefore, the gross margin over that period was 62.9%.

RMD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, ResMed Inc. reported a gross profit of 878.72M and revenue of 1.42B. Therefore, the gross margin over that period was 61.8%.

DXCM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, DexCom, Inc. reported an operating income of 323.00M and revenue of 1.26B, resulting in an operating margin of 25.6%.

RMD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, ResMed Inc. reported an operating income of 491.66M and revenue of 1.42B, resulting in an operating margin of 34.6%.

DXCM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, DexCom, Inc. reported a net income of 267.30M and revenue of 1.26B, resulting in a net margin of 21.2%.

RMD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, ResMed Inc. reported a net income of 392.59M and revenue of 1.42B, resulting in a net margin of 27.6%.